Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers want to see how well the drug enasidenib works in people with angioimmunoblastic T-cell lymphoma (AITL). The people in this study have AITL that came back or keeps growing after treatment. Their cancers also have a mutation (change) in the IDH2 gene.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
In this study, researchers want to see if adding stereotactic body radiation therapy (SBRT) to standard drug therapy is effective for people with estrogen receptor (ER)-positive HER2-positive oligometastatic breast cancer that has gotten worse at one metastatic site despite medical treatment. Oligometastatic breast cancer is cancer that has spread to a small number of parts of the body. SBRT delivers extremely precise, very intense doses of radiation to cancer cells.
Researchers want to see if giving stereotactic radiosurgery (SRS) after osimertinib is better than osimertinib alone for advanced lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that metastasized (spread) to the brain. Their cancers have a mutation (change) in the EGFR gene, and they are taking or planning to take osimertinib.
CAR T-cell therapy is a form of immunotherapy used to treat some adults with lymphoma. The treatment involves utilizing a patient's own T cells and genetically modifying them in the laboratory to recognize a protein on their cancer cells. The modified T cells, known as CAR T cells, are then returned to the patient to find and kill cancerous cells throughout the body.
Multiple myeloma that keeps growing after treatment can cause cancer cells to build up inside the bones. The cancer cells crowd out healthy blood cells and make abnormal proteins that cause discomfort. Researchers in this study want to find the best dose of KTX-1001 to treat multiple myeloma that grows after treatment.
Researchers want to find the best dose of lorlatinib to give with ramucirumab in people with lung cancer. They are also seeing how well this drug combination works. The people in this study have non-small cell lung cancer (NSCLC) that has metastasized (spread). In addition, their cancers have a fusion involving the ALK gene. A fusion gene is made when parts of two different genes in your body join together.
Sickle cell disease and beta-thalassemia are blood diseases caused by a genetic change (mutation) in hemoglobin, the protein in red blood cells that carries oxygen throughout the body. People with these diseases may be offered a stem cell transplant. Stem cell transplantation involves receiving healthy blood-forming cells (stem cells) from a donor to replace the diseased or damaged cells in the bone marrow.
Researchers are doing this study is to find the highest dose of a new cell therapy for people with leukemia. The people in this study have acute myelogenous leukemia (AML) that keeps growing even after treatment. They will get the new treatment with atezolizumab, an immune-boosting therapy.
